The prospect of curing cancer with the ease of a few taps on a mobile device is on the horizon. A team of scientists at Rice University has secured forty-five million dollars in funding from the Advanced Research Projects Agency for Health for their innovative implant-based treatment system.
This new technology has the potential to reduce cancer-related mortality rates by an impressive fifty percent. The core of their project revolves around developing “sense-and-respond implant technology.” This new approach aims to enhance the effectiveness of immunotherapy treatments, particularly for cancers that have traditionally proven challenging to treat.
Omid Veiseh, a bioengineer at Rice University and principal investigator for this project, envisions a transformative approach to cancer treatment.
He has explained that instead of confining patients to hospital beds with intravenous (IV) bags and external monitors, the team’s goal is to employ a minimally invasive procedure. This procedure would involve implanting a small device within the patient’s body.
BREAKING: Scientists developing implant to cure cancer in just 60 days — with goal to slash death rates by 50% – New York Post
There’ll be an app for that.
Curing cancer could soon be as easy as a few taps on your mobile, according to a team of scientists at Rice Univers… pic.twitter.com/dEbVS5415m
— BeatBuzzReport (@beatbuzzreport) September 29, 2023
This implant would have the capability to continuously monitor the progress of the patient’s cancer and, even more impressively, make real-time adjustments to their immunotherapy dosage as needed, Veiseh further expressed.
Operating the cancer curing implant ‘potentially with a smartphone’
In a manner similar to how diabetes is managed with insulin pumps, the proposed three-inch implant, referred to as the “hybrid advanced molecular manufacturing regulator” (HAMMR), is designed to administer immunotherapy drugs to the patient through a “closed loop” system.
This means that the implant would continuously monitor the patient’s condition and deliver the necessary immunotherapy drugs as required in a highly automated and responsive manner.
Moreover, these chargeable implant devices will have the capability to communicate wirelessly, potentially through a smartphone, researchers explained.
Eradicating the cancer in as little as 60 days
The researchers are optimistic that the implant will have a relatively short-term usage, with the potential to eliminate cancer in as little as sixty days.
Dr. Amir Jazaeri, a co-principal investigator and professor specializing in gynecologic oncology at the University of Texas MD Anderson Cancer Center, made mention of the current limitations of available diagnostic tools.
Moreover, these tools, such as radiologic tests, blood assays, and biopsies, offer only occasional and limited insights into the ever-changing and adaptive nature of cancer cells under therapy, explained Dr. Jazaeri.
Omid Veiseh revealed that the technology they are developing has a wide range of applications and can be used for peritoneal cancers affecting various organs, including the pancreas, liver, lungs, and others.
The research team consists of experts from diverse fields, spanning twenty laboratories in seven different states. This collaborative effort operates under the project name THOR, which stands for “targeted hybrid oncotherapeutic regulation.”
The initial clinical trial is planned so as to assess the effectiveness of the implant for recurrent ovarian cancer. The team has aspirations to commence human trials within the next five years.